Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
HAMPTON, N.J., May 17, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic melanoma and the Phase 1 dose-escalation study of varlilumab and nivolumab in multiple solid tumors, will be presented in oral presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago. Information in the abstracts is current as of the time of submission in February 2017.
- Abstract #109: “A Phase 2 study of glembatumumab vedotin, an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” Patrick A. Ott, M.D., Ph.D., Clinical Director of Dana-Farber Cancer Institute’s Melanoma Center and its Center for Immuno-Oncology, and Assistant Professor of Medicine at Harvard Medical School, will present results during the Clinical Science Symposium “Hitting the Target: Antibody-Drug Conjugates,” which begins on Monday, June 5, 2017 at 9:45 a.m. CDT.
- Abstract #3007: “Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.” Rachel E. Sanborn, M.D., co-director of the Providence Thoracic Oncology Program at Providence Cancer Center in Portland, Ore., will present results during the session “Developmental Therapeutics—Immunotherapy,” which begins on Monday, June 5, 2017 at 1:15 p.m. CDT.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Company Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected] Media Contact Dan Budwick Founder, 1AB Media (973) 271-6085 [email protected]
